A Randomized Trial of Angiotensin Receptor bLocker,Fimasartan, in Aortic Stenosis (ALFA Trial)
Status:
Unknown status
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
We hypothesized that fimasartan, a new generation ARBs, would improve exercise capacity and
decrease the rate of progression of AS by modifying hemodynamic factors and reducing adverse
LV remodeling favorably in patients with asymptomatic moderate to severe AS.
Phase:
Phase 4
Details
Lead Sponsor:
Seoul National University Hospital
Collaborators:
Boryung Pharmaceutical Co., Ltd Chonnam National University Hospital Korea University Anam Hospital Korea University Guro Hospital Samsung Medical Center Seoul National University Bundang Hospital Severance Hospital